As much as he may be right, this attack is in very poor taste coming from the CEO of the main competitor. By all means provide a feature comparison table and let customers make their minds up, but calling your competitor a “cancer” based on them not doing much open source work, or based on the company that owns them, that’s a moral judgement that competitors shouldn’t be making about each other in public.